E-viri
Recenzirano
Odprti dostop
-
COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?Sarzi-Puttini, Piercarlo; Giorgi, Valeria; Sirotti, Silvia; Marotto, Daniela; Ardizzone, Sandro; Rizzardini, Giuliano; Antinori, Spinello; Galli, Massimo
Clinical and Experimental Rheumatology, 03/2020, Letnik: 38, Številka: 2Journal Article
A severe outbreak of coronavirus disease 2019 (COVID-19) emerged in China in December 2019, and spread so rapidly that more than 200,000 cases have so far been reported worldwide; on January 30, 2020, the WHO declared it the sixth public health emergency of international concern. The two previously reported coronavirus epidemics (severe acute respiratory syndrome SARS and Middle East respiratory syndrome MERS) share similar pathogenetic, epidemiological and clinical features as COVID-19. As little is currently known about SARS-CoV-2, it is likely that lessons learned from these major epidemics can be applied to the new pandemic, including the use of novel immunosuppressive drugs.
